Author Archives: mmcdonald

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH^™

KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECH^TM performance as well as potentially stake new intellectual property claims.

Retatrutide is one of Eli Lilly and Company's^® leading next-generation GLP-1 drugs undergoing extensive trials in the weight loss space, where two current Phase 3 studies were recently reported to deliver average weight loss of 28.3% - or 70 pounds - when evaluating patients who stayed on the drug. Unlike the GLP-1 drugs currently on the market, retatrutide is a triple hormone receptor agonist, targeting each of GLP-1, glucagon, and GIP ("glucose-dependent insulinotropic polypeptide"). Retatrutide is currently administered only via weekly injections, whereas Lexaria's Study will examine oral dosing formulated via tablets and capsules.

Weight loss with retatrutide - which has not yet been approved by the FDA - seems to be higher than with any other GLP-1 drug on the market today, with an astonishing 65.3% of participants taking the 12mg dose of retatrutide achieving a BMI ("body mass index") of less than 30, meaning they no longer met the minimum BMI criteria for obesity.

Lexaria's investigation into retatrutide, if successful, would expand DehydraTECH's applicability to prospective triple-agonist weight-loss peptide drugs in late stages of development, that could potentially dominate the future market.

"This is a watershed moment for Lexaria's investigations into GLP-1 drugs," said Richard Christopher, CEO of Lexaria Bioscience. "We have already established the compatibility of our technology with today's leading GLP-1 drugs, but if we are likewise able to demonstrate benefits with the drugs of tomorrow like retatrutide, amycretin and others, then we will begin to show relevance to those drugs that will likely be on the market for the next 10 years or more."

Lexaria's large Study is investigating 18 different study arms to evaluate new and novel DehydraTECH^TM compositions that may be of interest to industry. Blood samples are being taken at multiple timepoints through a 24-hour post-dosing period to quantify the pharmacokinetic ("PK") performance of each composition. The primary goals of this Study are to investigate compatibility of retatrutide and amycretin with Lexaria's DehydraTECH^TM formulation and processing technology, centered around PK performance and tolerability. Retatrutide is owned by Eli Lilly and Company^®, whereas amycretin is owned by Novo Nordisk^®.

As is the case with all GLP-1 drugs on the market today, common side effects of next-generation retatrutide and amycretin GLP-1 drugs include nausea and gastrointestinal issues such as diarrhea and vomiting. With this Study and others planned, Lexaria is attempting to establish that DehydraTECH^TM processing of these drugs may lower the severity and instances of side effects while maintaining or improving efficacy.

This Study will also directly compare pill (tablet) formulations to capsules, to better understand the differences between absorption of the active drugs primarily through either the stomach (pills) or the intestine (capsules). Most oral GLP-1 peptide drugs on the market today rely on pill formulations that are primarily absorbed through the stomach.

As in Animal Study #1 announced on April 15th, this new Study will evaluate alternative formulations to the salcaprozate sodium (SNAC) technology currently incorporated in Novo Nordisk's^® oral Rybelsus^® and Wegovy^® tablet products. The present Study will include but not be limited to compositions using a different delivery enabling compound, sodium caprate, which has itself been shown to influence gastrointestinal absorption.

This is a self-sponsored Lexaria Study that is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development ("BD") program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference.

"We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference," said Richard Christopher, CEO of Lexaria Bioscience. "New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss."

BIO is the largest convention of its kind, with over 20,000 attendees expected from all corners of the global pharmaceutical and biotechnology industries, as well as their supporting sectors such as investors and finance professionals, and more. BIO is focused on intra-industry collaborations and meetings, with over 66,000 partnering meetings having taken place at the 2025 conference. Lexaria has already begun reserving meetings and will be fully booked for the event given the strong industry interest in its proprietary DehydraTECH^™ drug delivery platform.

BIO is only the latest example of a multi-faceted BD program that Lexaria quietly launched in order to inform prospective business partners of the benefits available through DehydraTECH^™. Although confidential information, by its nature, cannot be publicly disclosed, Lexaria's BD program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies from innovative smaller biotech developers to well-known global pharmaceutical giants.

While Lexaria's BD program has already developed a number of ongoing discussions, it continues to develop additional early-stage leads, and the Company intends to thoroughly evaluate each potential relationship, large and small, and ultimately only pursue those that are in the best interests of its shareholders. Additional information will be made available when appropriate.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's^® commercially available Wegovy^® tablets (the "Study").

"Lexaria is delighted to have received the independent ethics review board approval so quickly," said Richard Christopher, CEO of Lexaria Bioscience. "Lexaria is looking for this Study to provide the positive outcomes necessary to support commercial collaboration within the pharmaceutical industry related to Lexaria's demonstrated improvements in delivering oral GLP-1 drugs in real-world environments."

Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 ("GLP-1") studies such as Human Study #4 (GLP-1-H25-4), combined with pharmacokinetic ("PK") performance that matches or exceeds the Wegovy^® tablet control over a 5-week period. Previous Lexaria salcaprozate sodium ("SNAC")-inclusive DHT-sema single dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2) evidenced PK performance that matched or exceeded the Rybelsus^® control arm and also evidenced noteworthy safety and tolerability profiles.

The results of this Study are expected to be carefully reviewed by the pharmaceutical industry in order to evaluate the possibility of entering into commercial relationships focused on Lexaria's proprietary DehydraTECH technology.

Laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles for the Study have been performed. Third-party independent lab quality-control ("QC") testing of those test articles is currently underway and is expected to be complete in early June. Packaging of all the test articles suitable for the Study will be undertaken in parallel with this.

The design of the Study is now complete: a five-week parallel group design, investigating three separate arms to assess safety & tolerability and PK properties that will compare SNAC-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy^® tablets. The Study will be conducted under fasted pre-dose conditions.

The Study explores several new DehydraTECH enhancements not previously evaluated, which include but are not limited to the following two main improvements:

(1) First, an oral tablet DHT-sema composition will be used by Lexaria for the first time, as opposed to only the capsule compositions included in all our previous DHT GLP-1 studies. Novo Nordisk's^® Rybelsus^® and Wegovy^® oral semaglutide medications both use specially formulated tablets designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of the active ingredient - semaglutide - into the human body. For the first time ever, Lexaria has attempted to mimic and integrate certain properties of the Rybelsus^®/Wegovy^® SNAC-inclusive tablet delivery modality into its DHT-sema tablets to increase the likelihood of subsequent commercial pharmaceutical relationships.

(2) Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations are evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. As noted above, Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2), conducted in 2024 and 2025 which incorporated SNAC (but did not use tablets), were limited by single-dose study designs; therefore, of much shorter duration.

Lexaria currently expects dosing to begin in mid-June. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities

KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today released the second episode of Reformulated: Into the Mainstream, the Company's ongoing investor communications series.

The latest episode features CEO Rich Christopher in conversation with host Ana Berry. The discussion covers the recently announced extension of Lexaria's Material Transfer Agreement with a global pharmaceutical partner through year-end 2026, the Company's 2026 GLP-1 research priorities, and how ongoing business development activity fits within Lexaria's broader commercial strategy.

The second episode is available here: https://www.youtube.com/watch?v=WZaXvP-PpJM

"The extension reflects continued engagement around DehydraTECH and the data we expect to generate this year," said Rich Christopher, CEO of Lexaria. "Our focus remains on producing compelling clinical evidence and expanding the dialogue with potential partners across GLP-1 and beyond."

Additional episodes will be released periodically, covering Lexaria's clinical pipeline, intellectual property portfolio, and developments across the oral drug delivery landscape.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's^® commercially available Wegovy^® tablets (the "Study").

Submissions have now been entered to formally request the required ethics approval from an independent review board. Final laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles for the Study have been completed with third-party independent lab quality-control ("QC") testing of such test articles currently underway. It is anticipated that receipt of ethics approval, completion of QC testing and packaging of the qualified test articles (the "Pre-Dosing Tasks") will occur by early June.

The design of this Study is complete, subject to any modifications which may or may not be required by the ethics reviewers. The Study is planned to be a five-week parallel group design, investigating three separate arms to assess safety & tolerability and pharmacokinetic ("PK") properties that will compare salcaprozate sodium ("SNAC")-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy^® tablets. The Study will be conducted under fasted pre-dose conditions. Lexaria hopes to preserve the superior safety and tolerability profiles as evidenced in previous Lexaria GLP-1 studies such as Human Study #4 (GLP-1-H25-4), combined with PK performance that matches or exceeds that of the commercial oral tablet as also evidenced in previous Lexaria SNAC-inclusive DHT-sema studies such as Human Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2; which, incidentally, also evidenced noteworthy safety and tolerability profiles).

The results of this Study are expected to be carefully reviewed by the pharmaceutical industry in order to evaluate the possibility of entering into commercial relationships focused on Lexaria's proprietary DehydraTECH technology.

What's New?

This Study explores several new DehydraTECH enhancements not previously evaluated, which include but are not limited to the following two main improvements:

1. First, an oral tablet DHT-sema composition will be used by Lexaria for the first time, as opposed to only the capsule compositions included in all our previous DHT glucagon-like peptide-1 ("GLP-1") studies. Novo Nordisk's^® Rybelsus^® and Wegovy^® oral semaglutide medications both use specially formulated tablets designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of the active ingredient - semaglutide - into the human body. For the first time ever, Lexaria has attempted to mimic and integrate certain properties of this Rybelsus^®/Wegovy^® tablet delivery modality into its DHT-sema tablets. Lexaria believes this may increase the likelihood of subsequent commercial pharmaceutical relationships.

2. Second, both the Lexaria DHT-sema tablet and capsule test articles will be formulated with SNAC, which will be the first time these formulations are evaluated over a multi-dose, multi-week time period in humans. The five-week dosing duration of the Study is expected to be long enough to reach so-called steady-state, which is when drug concentrations in the body reach a constant concentration. Earlier DHT-sema human pilot studies GLP-1-H24-1 and GLP-1-H24-2, as noted above, that Lexaria conducted in 2024 and 2025 that also used SNAC (but did not use tablets), were limited by single-dose study designs; therefore, of much shorter duration. Novo Nordisk's^® branded Rybelsus^® and Wegovy^® semaglutide-based products are both formulated with SNAC.

Lexaria will update its stakeholders once the Pre-Dosing Tasks have been achieved. Based on the expected timelines, Lexaria anticipates dosing to begin in mid-June. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy

KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today announced the launch of Reformulated: Into the Mainstream, an ongoing investor communications series designed to support transparency, consistent engagement, and alignment with shareholders and the broader investment community.

As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews and management discussions with Lexaria leadership. Episodes will cover company updates alongside broader market and sector trends, providing investors with consistent context around Lexaria's business and the environment in which it operates.

The inaugural episode features an in-depth conversation with Lexaria CEO Rich Christopher and host Ana Berry. The discussion covers the DehydraTECH platform and its applicability across GLP-1 therapies, CBD, antivirals, and other compounds; the Company's focus on the GLP-1 market, which generated approximately $75 billion in worldwide revenue in 2025; the completion of five human GLP-1 studies across semaglutide, tirzepatide, and liraglutide; and Lexaria's multi-pronged commercial strategy, including outlicensing activity under an active Material Transfer Agreement with a global pharmaceutical company.

The first installment of Reformulated: Into the Mainstream is now available here: https://www.youtube.com/watch?v=KG9dCWS6x6I

"Transparency and consistent communication are foundational to building long-term trust with shareholders," said Rich Christopher, CEO of Lexaria. "The series reflects our commitment to providing ongoing insight into how we think about oral drug delivery, the GLP-1 opportunity, and the disciplined execution required to advance DehydraTECH toward commercial partnerships."

New episodes will be released periodically, expanding into additional areas of Lexaria's clinical pipeline, intellectual property portfolio, and industry developments.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH^™ technology in a pre-clinical setting.

The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams.

Over the past 12 months, Lexaria has taken important steps in advancing its GLP-1 development program. This includes recently announced progress in each of its 2026 R&D studies: Human Study #7; Animal Study #1; and Animal Study #2. All of these studies are within the GLP-1 sector and have been designed with the goal of providing fulsome evidence to better allow additional collaboration and potential licensing of Lexaria's technology.

Each of the studies mentioned above are in process and are fully funded with existing corporate resources. Results are expected during Q3 and Q4 of this calendar year.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

• Contracts signed for Animal Study #2: GLP-1-A26-2

• Amycretin and retatrutide to be tested for compatibility with DehydraTECH

KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property claims.

Contracts with the CRO have been signed; Study design has been completed; formulation manufacturing is underway; and dosing is expected to begin within 30 days.

"The two most successful GLP-1 drugs on the market today are semaglutide and tirzepatide, accounting for more than 95% of the over $70 billion in revenue generated by GLP-1 drugs during 2025," said Richard Christoper, CEO of Lexaria Bioscience. "But, next-generation drugs that offer improved efficacy are under development and Lexaria is intent to establish DehydraTECH's benefits in these drugs that have not yet reached the marketplace."

This is a large Study that will investigate 18 different study arms to evaluate new and novel DehydraTECH compositions. Blood samples will be taken at multiple timepoints through a 24-hour post-dosing period to quantify the pharmacokinetic ("PK") performance of each composition. The primary goals of this Study will be to investigate compatibility of amycretin and retatrutide with DehydraTECH formulation and processing technology, centered around PK performance and tolerability. Amycretin is owned by Novo Nordisk^®, and retatrutide is owned by Eli Lilly and Company^®.

As is the case with all GLP-1 drugs on the market today, common side effects of next-generation amycretin and retatrutide include nausea and gastrointestinal issues such as diarrhea and vomiting. With this Study and others, Lexaria will hope to establish that DehydraTECH processing of these drugs may lower the severity and instances of side effects.

This Study will also directly compare pill (tablet) formulations to capsules, to better understand the differences between absorption of the active drugs primarily through either the stomach (pills) or the intestine (capsules). Most oral GLP-1 drugs on the market today rely on pill formulations that are primarily absorbed through the stomach.

As in Animal Study #1 announced on April 15, this new Study will evaluate alternative formulations to salcaprozate sodium (SNAC) currently incorporated in Novo Nordisk's^® oral Rybelsus^® and Wegovy^® tablet products. The present Study will include but not be limited to compositions using a different delivery enabling compound, sodium caprate, which has itself been shown to influence gastrointestinal absorption.

Lexaria will update its stakeholders once dosing has begun. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

600,000 New Wegovy® Pill Prescriptions Written in First Two Months

KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market.

The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy^®, was approved by the US Food and Drug Administration ("FDA") on December 22, 2025 and launched in the US in January 2026. Prior to that, Rybelsus^® was the only FDA approved GLP-1 drug available in pill form, but it was approved for diabetes control and only used secondarily (or, "off label") for weight loss.

Within less than the first two months of its launch, Novo Nordisk^® had disclosed that over 600,000 prescriptions for the Wegovy^® pill had been written, and will report on its first-quarter sales including the Wegovy^® pill in May. Both the Wegovy^® injectable and the Wegovy^® pill contain the same active drug: semaglutide, with which Lexaria has conducted extensive testing to determine compatibility with Lexaria's DehydraTECH^™ technology.

According to Global Data Healthcare, 51% of the growth in Wegovy^® revenue between 2026 and 2031 is expected to come from the pill format, with injectable semaglutide expected to reach peak revenue in 2030, when Novo Nordisk's Wegovy^® semaglutide franchise is expected to reach $15.9 billion in annual revenue. This will be quite an achievement since 2025 semaglutide revenue derived from Wegovy^® was 100% in the injectable category, whereas 2031 revenue from Wegovy^® products is expected to be 17% from pills.

As Lexaria's press release of March 24 noted, TD Cowen^® raised their previous 2030 sales forecast of the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis is forecasting sales of $180 billion by 2035, while UBS Investment Bank^® expects 2029 GLP-1 sales to reach $126 billion.

It is not possible to know in advance, what overall portion of the GLP-1 market will be captured by the oral pill format vs. the traditional injectable format; but, if the Wegovy^® based semaglutide revenue projections are any indication, it could certainly be 17% or higher within a few short years of product launch. In fact, according to a Novo Nordisk^® executive, oral GLP-1 drugs may account for as much as 33% of the broader GLP-1 market by that time. Based on the various GLP-1 revenue forecasts ranging from $101 billion to $180 billion, this could imply an oral pill sector ranging in size from $17 billion to $60 billion by the mid 2030's.

This oral pill GLP-1 market is the specific market sector that Lexaria's technology is focused on. As noted within an article appearing on CNBC, "Novo Nordisk's new Wegovy^® GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections." If this proves to be a sustainable trend, then a successful GLP-1 pill sector could power the broader GLP-1 market to become even larger than original projections and provide enhanced opportunities for Lexaria's DehydraTECH^™.

The onset of GLP-1 drugs has radically changed the diabetes and weight-loss market sectors. The more recent onset of the GLP-1 oral pill sector is now driving revenues faster and further than injectable GLP-1 drugs alone. Lexaria's DehydraTECH^™ has demonstrated performance enhancing abilities across three prominent GLP-1 drugs: semaglutide, tirzepatide and liraglutide; and Lexaria's announced 2026 Research & Development program intends to explore DehydraTECH's possible expanded applicability to next generation GLP-1 drugs including, but not limited to, retatrutide and amycretin. Lexaria remains in discussions with pharmaceutical companies related to their potential interest in DehydraTECH^™ for their oral GLP-1 strategies.

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

Contracts signed for Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

Contracts with the CRO have been signed, materials sourcing is underway, and Study design is being finalized with the goal of beginning dosing within approximately 60 days.

"The global arms race in diabetes control, weight loss and other GLP-1-indicated areas of treatment is intensifying with recent new oral drugs being approved by the Food and Drug Administration ("FDA")," said Richard Christoper, CEO of Lexaria Bioscience. "With tens of billions of dollars in new annual revenue soon expected in the sector, there has never been a better time to stake new legal IP claims in order to offer the pharmaceutical industry improved performance including reducing side effects, while improving Lexaria's probabilities of becoming an indispensable provider of improved drug delivery technology."

While final design parameters of this Study are ongoing, it is expected to utilize Sprague-Dawley rats with 8 to 11 separate arms evaluating a number of different novel compositions. Blood samples will be taken at multiple timepoints through an 8-24-hour post-dosing period to quantify the pharmacokinetic performance of each composition. In addition, the Study will also measure drug concentrations in the brain since DehydraTECH has, in the past, evidenced apparent superior absorption of active ingredients into brain tissue, an area of intense interest due to the fact that GLP-1 drug performance is increasingly understood to include or even depend upon involvement of brain neurochemistry, thus making brain biodistribution vital. There will be one reference arm using an existing DHT-sema composition and another reference arm using an existing DHT-CBD composition. Lexaria intends to leverage the wealth of study data that we have amassed from previous work by utilizing our proprietary historical data and the reference arms as baseline comparators to the current Study results as we search for areas of superiority.

One of the novel objectives of this Study will be to evaluate alternative/additive formulations to SNAC (salcaprozate sodium) which is currently in use by Novo Nordisk® with their oral Rybelsus® and Wegovy® tablet products. If Lexaria is able to establish novel new formulations with superiority to SNAC, we may be able to register new patents and create valuable new proprietary IP and an industry alternative to SNAC that could be of interest within the keenly competitive GLP-1 sector.

Lexaria will update its stakeholders once dosing has begun. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.